Acute Kidney Injury Market to Grow at a CAGR of Approximately 8% by 2032 | DelveInsight

21 Jun 2022
www.prnewswire.com
Biosimilar
The dynamics of acute kidney injury market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, incremental healthcare spending across the world and the expected launch of the emerging therapies during the forecast period.
LAS VEGAS, June 21, 2022 /PRNewswire/ -- DelveInsight's
Acute Kidney Injury Market Insights report includes a comprehensive understanding of current treatment practices, Acute Kidney Injury emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.
Key Takeaways from the Acute Kidney Injury Market Report
As per DelveInsight analysis, the Acute Kidney Injury market size in the 7MM was approximately
USD 5.4 billion in 2020.
As per DelveInsight analysis, the total Acute Kidney Injury incident cases in the 7MM were approximately
10.9 million in 2020.
The United States contributed to the largest incident-patient share (mortality adjusted), acquiring
~ 34.09% of the 7MM in 2020
Rising incidence of AKI will provide a larger window of opportunity for new treatment and prevention options
The pipeline of AKIAKI is quite robust with diverse products strengthening targeting prophylaxis of AKI in several complications such as Sepsis and post-cardiac-surgery mainlyLeading acute kidney injury companies such as
The Acute Kidney Injury therapies in the pipeline include
, and others.
The key driver for the surge in acute kidney injury market size is the rise in the number of incident cases of acute kidney injury.
Discover more about therapies set to grab major acute kidney injury market share @
Acute kidney injury (AKI), also known as acute renal failure (ARF), is a disorder that causes progressive azotemia with or without oliguria over a period of hours or days. Acute kidney injury is defined as a sudden loss of renal function, clinically expressed as an acute reversible surge in nitrogen waste products as measured by blood urea nitrogen and serum creatinine levels over hours to weeks. Acute kidney injury causes an abrupt loss in renal function, which results in waste product retention, electrolyte abnormalities, and changes in volume status. Acute kidney injury is classified into prerenal, postrenal, and intrinsic renal.
Many people with acute kidney injury are asymptomatic, while others experience generalized non-specific acute kidney injury symptoms such as nausea, vomiting, weakness, dizziness, lower back pain, passing less urine than usual, unexplained loss of appetite, feeling sick or vomiting, shortness of breath, and swelling of the legs or other body parts. An increase in serum creatinine and a reduction in urine output are commonly used for acute kidney injury diagnosis.
Acute Kidney Injury Epidemiology Segmentation
As per DelveInsight, there were approx
10.9 million acute kidney injury incident cases in the 7MM in 2020.
Among the EU5 countries, Germany had the highest acute kidney injury incident population in 2020.
The
Acute Kidney Injury market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into
Total Incident Population of Acute Kidney Injury (AKI) in Hospitalized Patients
Mortality Adjusted Incident Population of AKI in Hospitalized Patients
Stage-specific Incident Population of AKI
Age-specific Incident Population of AKI
Download the report to understand which factors are driving acute kidney injury epidemiology trends @
Acute Kidney Injury Treatment Market
For the past several years; it has been observed that the current acute kidney injury treatment is primarily supportive in character, with no therapeutic approaches demonstrating benefit in treating the condition. Off-label acute kidney injury medications used to treat AKI include
ACE inhibitorsACE inhibitors, angiotensin II-receptor blockers (ARBs), diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), and renal replacement therapy (RRT). Monitoring urine output and, at first, serum creatinine levels (SCr) numerous times each day is a cornerstone of the therapy for all patients with acute kidney injury. It is also indicated to correct electrolyte imbalances, quit or adjust nephrotoxic medicines, and dose-adjust pharmaceuticals with renal elimination.
To know more about Acute Kidney Injury treatment, visit @
Acute Kidney Injury Pipeline Therapies and Key Companies
bRESCAP: Alloksys
ANG-3777 (BB3): Angion Biomedica/ Vifor Pharma
Ilofotase alfa: AM Pharma
Ruconest (Conestat alfa): Pharming Technologies
Learn more about the acute kidney injury medications @
Acute Kidney Injury Market Dynamics
Treatment-related adverse effects are quite rare, resulting in
successful acute kidney injury treatment choices. Moreover, patients have
easy access to reimbursements since their ailment necessitates long-term management, such as dialysis. In addition, several
government activities are being undertaken by adopting various programs concerning acute kidney injury, which is expected to improve the global AKI prospect and thus bolster the actue kidney injury market.
Furthermore, several
biomarkers, including
NGAL, Cystatin-C, and others, are being investigated for use in acute kidney injury diagnosis. The validation of these new biomarkers could provide new methods for detecting the start and severity of kidney injury. Future research in the acute kidney injury market is underway with the goal of better understanding of the underlying processes and, as a result, improve outcomes for AKI patients.
Moreover, a
robust pipeline with a novel mechanism of action and increasing incidence are major market drivers of the acute kidney injury market. Additionally, the acute kidney injury pipeline is also expected to change the current dynamics of the acute kidney injury market, which presently comprises biologics and molecules with new mechanisms of action like
However, there are several barriers to the acute kidney injury market growth. One such factor is the
lack of awareness. If the patients have cardiac issues, the situation becomes even more complex. Moreover, long-term health repercussions, as well as longer hospital stays and high health-care expenses, highlight AKIAKI's enormous societal impact. In addition, several risk factors, such as diabetes and heart failure, have substantial implications for patients' quality of life, making it challenging to develop promising future interventions and thus hindering the acute kidney injury market growth.
Scope of the
Market Report
Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key
Key
Therapeutic Assessment: Acute kidney injury current marketed and emerging therapies
Market Dynamics: Acute kidney injury market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views,
Discover more about acute kidney injury drugs in development @
Acute Kidney Injury Clinical Trials
Table of Contents
Get in touch with our Business executive @
Healthcare Due Diligence Services
Related Reports
Acute Kidney Injury Pipeline Insight, 2022 report provides comprehensive insights about pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key acute kidney injury companies including
Acute Kidney Injury Epidemiology Forecast
Acute Kidney Injury Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted acute kidney injury epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Chronic Kidney Disease Pipeline Insight, 2022 report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key chronic kidney disease companies, including
Bayer, AstraZeneca, Celgene, Ipsen, among others.
Anemia in Chronic Kidney Disease Pipeline Insight, 2022 report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key anemia in chronic kidney disease companies, including
Diabetic Kidney Disease Pipeline Insight, 2022 report provides comprehensive insights about pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key diabetic kidney disease companies, including
Polycystic Kidney Disease Pipeline Insight, 2022 report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key anemia in polycystic kidney disease companies, including
Kidney Transplant Rejection Pipeline
Kidney Transplant Rejection Pipeline Insight, 2022 report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products. It also covers the key anemia in kidney transplant rejection companies, including
Other Trending Reports
Pediatric Growth Hormone Deficiency Market
|
|
X-Linked Retinitis Pigmentosa Market
|
|
|
Blastic Plasmacytoid Dendritic Cell Neoplasm Market |
Bevacizumab Biosimilars Insight | Bacterial Conjunctivitis Market |
FENEBRUTINIB Market | Peripherally Inserted Central Catheter Devices Market | Cardiac Biomarkers Testing Devices Market
Related Healthcare Blogs
Acute Kidney Injury Market Outlook
Acute Kidney Injury Treatment Market
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
.
Connect with us on LinkedIn
|Facebook|Twitter
Contact Us
[email protected]
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.